Regenxbio

OverviewSuggest Edit

Regenxbio is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders, as well as clinical trails in therapeutic areas.
TypePublic
Founded2009
HQRockville, MD, USMap
Websiteregenxbio.com
Overall CultureA+More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2020)257(+34%)
Revenue (FY, 2019)$35.2 M(-83%)
Share Price (Feb 2021)$46.3 (+4%)
Cybersecurity ratingCMore

Key People/Management at Regenxbio

Olivier Danos

Olivier Danos

Chief Scientific Officer
Allan Fox

Allan Fox

Chairman of the Board
Vit Vasista

Vit Vasista

Chief Financial Officer
Ken Mills

Ken Mills

Director, President and Chief Executive Officer
Jerry Karabelas

Jerry Karabelas

Lead Independent Director
Luke M. Beshar

Luke M. Beshar

Independent Director
Show more

Regenxbio Office Locations

Regenxbio has an office in Rockville
Rockville, MD, US (HQ)
9600 Blackwell Rd #210
Show all (1)

Regenxbio Financials and Metrics

Regenxbio Revenue

Regenxbio's revenue was reported to be $35.23 m in FY, 2019
USD

Revenue (Q3, 2020)

98.9m

Gross profit (Q3, 2020)

81.5m

Gross profit margin (Q3, 2020), %

82.4%

Net income (Q3, 2020)

8.8m

EBIT (Q3, 2020)

14.0m

Market capitalization (5-Feb-2021)

2.0b

Closing stock price (5-Feb-2021)

46.3

Cash (30-Sept-2020)

93.2m

EV

1.9b
Regenxbio's current market capitalization is $2 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

7.6m4.6m10.4m218.5m35.2m

Cost of goods sold

98.0k98.0k6.0k8.2m

Gross profit

7.5m4.5m10.4m27.0m

Gross profit Margin, %

99%98%100%77%
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.1m393.0k2.4m125.0k455.0k6.6m1.3m132.4m40.0m5.3m884.0k7.9m14.7m17.6m16.6m98.9m

Cost of goods sold

44.0k30.0k49.0k22.0k6.0k3.9m517.0k29.0k1.9m2.5m3.4m4.7m17.4m

Gross profit

1.1m363.0k2.3m103.0k6.6m36.2m4.8m855.0k6.0m12.2m14.2m11.9m81.5m

Gross profit Margin, %

96%92%98%82%100%90%90%97%76%83%81%72%82%
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

54.1m24.8m46.7m75.6m69.5m

Accounts Receivable

2.1m1.0m473.0k8.6m38.1m

Prepaid Expenses

1.0m1.8m5.3m5.7m6.5m

Current Assets

118.1m93.4m168.0m337.9m345.0m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

205.3m35.5m30.1m28.1m82.0m57.6m59.9m71.9m106.9m142.4m55.9m55.1m79.6m69.4m94.2m93.2m

Accounts Receivable

2.0m783.0k679.0k228.0k50.0k884.0k26.0m739.0k2.6m8.4m9.7m19.2m44.5m42.9m122.1m

Prepaid Expenses

1.4m1.2m1.5m2.2m1.8m2.4m3.2m4.7m6.3m6.0m6.9m7.4m9.7m16.1m

Current Assets

215.5m105.6m97.9m96.6m148.8m165.8m172.2m262.7m293.3m386.4m303.9m359.5m360.2m338.2m329.1m387.0m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(22.8m)(63.0m)(73.2m)99.9m(94.7m)

Depreciation and Amortization

80.0k544.0k2.7m4.0m7.2m

Accounts Payable

590.0k186.0k2.6m(218.0k)1.5m

Cash From Operating Activities

(22.5m)(48.6m)(58.0m)104.6m(107.7m)
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(17.6m)(10.8m)(25.2m)(43.4m)(22.0m)(36.5m)(57.2m)104.2m114.8m95.6m(32.2m)(33.7m)(68.3m)(40.0m)(73.8m)(65.0m)

Depreciation and Amortization

43.0k48.0k104.0k264.0k554.0k1.3m2.0m834.0k1.7m2.7m1.6m3.4m5.2m2.0m4.1m6.3m

Accounts Payable

317.0k(182.0k)930.0k3.6m2.5m2.7m1.1m477.0k(340.0k)156.0k316.0k1.8m5.3m3.1m4.1m9.9m

Cash From Operating Activities

(18.1m)(7.9m)(16.3m)(28.1m)(17.5m)(27.0m)(44.2m)58.1m128.3m108.8m(29.3m)(53.0m)(82.2m)(35.6m)(57.1m)(93.5m)
show all
USDQ3, 2015

Financial Leverage

1 x
Show all financial metrics

Regenxbio Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

Learn more about our premium products
SecurityScorecard logo

Regenxbio Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Regenxbio Online and Social Media Presence

Regenxbio's Trends

Embed Graph

Regenxbio Company Culture

  • Overall Culture

    A+

    91/100

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    95/100

Learn more on Comparably

Regenxbio News and Updates

June 05, 2018

Optogenetic Market 2018 Enthralling Growth at A CAGR Of 17% | By Product Type Light Instruments, Actuators, Sensors – Declares MRFR

This report provides in-depth qualitative and overall analysis of the” Optogenetic Market” on a global and regional level from 2018 to 2023. The study also provides a comprehensive review of restraints, Market Dynamics, drivers and opportunities along with their impact on the overall market. The rep…
May 06, 2018

3 Things In Biotech, May 5: Mallinckrodt Snubbed, Regenxbio Races, Portola Surprises

April 18, 2018

OncoSec: The Underlying Science Of ImmunoPulse Powers A Potential Winner

April 17, 2018

Rounds Report: Regenxbio Surged Higher While Celldex Tumbled Due To A Negative Clinical Binary

April 10, 2018

BioSci Rounds Report: Regenxbio Surged, Geron Trading Reversed And Dexcom G6 Approved

December 21, 2017

Optogenetic Market Demonstrate Immense Growth Potential at ~176% of CAGR By 2023

This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the global Optogenetic Market over the forecast period. Posted via Industry Today. Follow us on Twitter @IndustryToday

Regenxbio Blogs

March 01, 2021

REGENXBIO Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights

ROCKVILLE, Md. , March 1, 2021 /PRNewswire/ -- Pivotal program for subretinal delivery of RGX-314 for the treatment of wet AMD is active and enrolling patients; expected to support BLA filing in 2024 Phase II trials of RGX-314 utilizing in-office suprachoroidal delivery for treatment of wet AMD and
February 22, 2021

REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , Feb. 22, 2021 /PRNewswire/ --  REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, March 1, 2021 , at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2020 , and recent operational highlights.
February 16, 2021

REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD

ROCKVILLE, Md. , Feb. 16, 2021 /PRNewswire/ -- RGX-314 using subretinal delivery continues to be generally well-tolerated at all dose levels Positive interim update from Cohorts 4 and 5 at 1.5 years after RGX-314 administration Durable treatment effect observed with stable visual acuity, decreased
February 08, 2021

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 17th Annual WORLDSymposium™ 2021

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 17th Annual WORLDSymposium™ 2021 Content Import Mon, 02/08/2021 - 14:29 REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-12…
February 01, 2021

REGENXBIO Announces Presentations at the 17th Annual WORLDSymposium™ 2021

ROCKVILLE, Md. , Feb. 1, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and nine poster presentations will be presented at the 17th Annual WORLD Symposium ™, taking place virtually from February 8 through 12, 2021 .
January 12, 2021

REGENXBIO Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

REGENXBIO Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares Content Import Tue, 01/12/2021 - 16:06 REGENXBIO Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase…
Show more

 Regenxbio Frequently Asked Questions

  • When was Regenxbio founded?

    Regenxbio was founded in 2009.

  • Who are Regenxbio key executives?

    Regenxbio's key executives are Olivier Danos, Allan Fox and Vit Vasista.

  • How many employees does Regenxbio have?

    Regenxbio has 257 employees.

  • What is Regenxbio revenue?

    Latest Regenxbio annual revenue is $35.2 m.

  • What is Regenxbio revenue per employee?

    Latest Regenxbio revenue per employee is $137.1 k.

  • Who are Regenxbio competitors?

    Competitors of Regenxbio include Evotec, BlueRock Therapeutics and Aptamer Group.

  • Where is Regenxbio headquarters?

    Regenxbio headquarters is located at 9600 Blackwell Rd #210, Rockville.

  • Where are Regenxbio offices?

    Regenxbio has an office in Rockville.

  • How many offices does Regenxbio have?

    Regenxbio has 1 office.